

Please type a plus sign (+) inside this box.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	New Application
Filing Date	
First Named Inventor	Becker, et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	R0079C-REG

J0932 U.S. PTO  
10/02/03

01/02/02

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
TNT	✓ A1	3,960,861		Danilewicz, et al	June 1, 1976	260/256.4
	✓ A2	4,044,136		Danilewicz, et al	Aug. 23, 1977	424/251
	✓ A3	4,686,228		Campbell, et al	Aug. 11, 1987	514/307
TNT	✓ A4	6,103,738		Collis, et al	Aug. 15, 2000	514/311

Class/subclass

**FOREIGN PATENT DOCUMENTS**


Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
TNT	✓ B1	✓ WO	98/30560	A1	Pfizer	July 16, 1998		
TNT	✓ B2	✓ GB	1,062,357		Pfizer	March 22, 1967		
TNT	✓ B3	✓ DE	27,57,925	A1	Bayer AG	June 28, 1979		

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examin er Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
TNT	✓ C1	GUPTA, et al., "Drugs Acting on the Central Nervous System. Syntheses of Sub- stituted Quinazolones and Quanzolines and Triazepino- and Triazocinoquina- zolones," <i>J. Med. Chem.</i> , 1968, 392-395, 11(2),	
	✓ C2	LEONARDI, et al., "Synthesis, Pharmacological Evaluation, and Structure - Activity Relationship and Quantitative Structure - Activity Relationship Studies on Novel Derivatives of 2,4-Diamino-6,7-dimethoxyquinazoline $\alpha_1$ -Adrenoceptor Antagonists", <i>J. Med. Chem.</i> , 1999, 427-437, 42 .	
	✓ C3	MENZIANI, et al., "Relevance of Theoretical Molecular Descriptors in Quantitative Structure - Activity Relationship Analysis of $\alpha_1$ -Adrenergic Receptor Antagonists," <i>Bioorg., Med. Chem.</i> , 1999, 2437-2451, 7(11) .	
	✓ C4	VILLALORGO, et al., "Solid-Phase Synthesis of 3H-Quinazolin-4-ones Based on an Aza Wittig-Mediated annulation Strategy", <i>Synlett</i> , 1998, 1405-1407, 12.	
	✓ C5	WOLLWEBER, et al., "3-Amino-2H-1,2,4-benzothiadiazin-1,1-dioxide mit antihypertensiver und potentieller diabetogener Wirkung", <i>Arzneim.-Forsch.</i> , 1981, 279-88, 31(2).	

Examiner  
SignatureDate  
Considered

3/31/03

Please type a plus sign (+) inside this 

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

# 3

Substitute for form 1449A/PTO

# **SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/040,319
Filing Date	January 2, 2002
First Named Inventor	Beck r, Cyrus K phra t al.
Group Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	R0079C-REG

Sheet 1 of 1

## **U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
TMT	B4 ✓	WO	00/55143	A1	F. Hoffmann- La Roche AG, Switzerland	09-21-2000		

## **OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>

Examiner  
Signature



Date  
Considered

9/2/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
Doc. #118091v1